Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Phase 3 Terminated 130 enrolled Sumitomo Pharma Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.

Timeline

Start: 2006-04
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amrubicin	Small molecule	—	—

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Summary

Timeline

Drugs

Indications